Trump’s new FDA commissioner has a huge decision to make

Partner Bill Schultz wrote an Op-Ed for The Washington Post about marketing off-label uses of prescription drugs and other decisions facing new FDA Commissioner Scott Gottlieb.

Read the full op-ed here.

Related practices
Related people
Media contact

Katie Munroe
Email | 202.778.1871